MicroRNAs (mi RNAs) repress gene expression by binding to complementary sequences in the 3ʹ untranslated region (3ʹ UTR) of mRNAs to target them for degradation and thereby prevent their translation 1 . Considering that more than 1,000 individual miRNA genes have been identified, that an individual miRNA can target hundreds or thousands of different mRNAs, and that an individual mRNA can be coordinately suppressed by multiple different mi RNAs, the miRNA biogenesis pathway therefore has an important role in gene regulatory networks. Over the past decade, it has emerged that mi RNAs have crucial roles in cancer. Propelled by the original publication that described the deletion of the miR-15 and miR-16 loci in the majority of samples from patients with B cell chronic lymphocytic leukaemia (B-CLL), a plethora of subsequent publications described altered miRNA expression in diverse types of cancer 2, 3 . Functionally, it has been shown through both loss-of-function and gain-of-function experiments in human cancer cells, mouse xenografts, transgenic mouse models and knockout mouse models that mi RNAs have key roles in cancer initiation, progression and metastasis 4, 5 . The first example was provided by enforced expression of the miR-17~92 cluster, the so-called oncomiR-1, that acted with MYC to accelerate tumour development in a mouse model of B cell lymphoma 6 . Certain other mi RNAs can function as tumour suppressors: for example, the let-7 family of mi RNAs targets important oncogenes such as MYC, RAS family members (HRAS, KRAS and NRAS) and high-mobility group AT-hook 2 (HMGA2) to suppress tumour growth [7] [8] [9] . Therefore, cancer-associated changes in miRNA expression patterns are emerging as promising diagnostic markers that often correlate with disease progression and patient survival. This pathway might also represent a new therapeutic target for multiple types of cancer 2 . Mechanistically, mi RNAs can control cell proliferation, differentiation, survival, metabolism, genome stability, inflammation, invasion and angiogenesis to affect tumour development.
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. Considering that more than 1,000 individual miRNA genes have been identified, that an individual miRNA can target hundreds or thousands of different mRNAs, and that an individual mRNA can be coordinately suppressed by multiple different mi RNAs, the miRNA biogenesis pathway therefore has an important role in gene regulatory networks. Over the past decade, it has emerged that mi RNAs have crucial roles in cancer. Propelled by the original publication that described the deletion of the miR-15 and miR-16 loci in the majority of samples from patients with B cell chronic lymphocytic leukaemia (B-CLL), a plethora of subsequent publications described altered miRNA expression in diverse types of cancer 2, 3 . Functionally, it has been shown through both loss-of-function and gain-of-function experiments in human cancer cells, mouse xenografts, transgenic mouse models and knockout mouse models that mi RNAs have key roles in cancer initiation, progression and metastasis 4, 5 . The first example was provided by enforced expression of the miR-17~92 cluster, the so-called oncomiR-1, that acted with MYC to accelerate tumour development in a mouse model of B cell lymphoma 6 . Certain other mi RNAs can function as tumour suppressors: for example, the let-7 family of mi RNAs targets important oncogenes such as MYC, RAS family members (HRAS, KRAS and NRAS) and high-mobility group AT-hook 2 (HMGA2) to suppress tumour growth [7] [8] [9] . Therefore, cancer-associated changes in miRNA expression patterns are emerging as promising diagnostic markers that often correlate with disease progression and patient survival. This pathway might also represent a new therapeutic target for multiple types of cancer 2 . Mechanistically, mi RNAs can control cell proliferation, differentiation, survival, metabolism, genome stability, inflammation, invasion and angiogenesis to affect tumour development.
Although individual mi RNAs can have either oncogenic or tumour-suppressive function, several studies have shown that miRNA expression is globally suppressed in tumour cells compared with normal tissue, suggesting that miRNA biogenesis might be impaired in cancer 10, 11 . Indeed, the expression levels of miRNAprocessing machinery components such as the ribonuclease III (RNase III) DROSHA and DICER1 are decreased in some cancers, such as lung cancer, ovarian cancer and neuroblastoma [12] [13] [14] . Additionally, low DROSHA or DICER1 expression levels are associated with advanced tumour stage and poor clinical outcome in patients with neuroblastoma and patients with ovarian cancer 13, 14 . Support that this global suppression can have a causative role in cancer was initially provided by the demonstration that genetic deficiency of components of the miRNA biogenesis pathway can accelerate tumour growth in a mouse model of lung cancer 15 . Although this work provided proof-of-concept that the miRNA biogenesis pathway can have an important role in cancer progression, it is the recently reported mutations in and dysregulation of miRNA biogenesis pathway components that highlight the pathophysiological relevance of the miRNA biogenesis machinery in human tumours [16] [17] [18] [19] [20] [21] [22] [23] [24] . Moreover, the recent discovery of certain molecular and cellular mechanisms that control miRNA biogenesis provided compelling evidence that disruption of this pathway is crucially important for a wide variety of paediatric and adult cancers.
In this Review, we discuss what is known about dysregulation of the miRNA biogenesis pathway in cancer, summarize the growing evidence that germline mutations
Post-transcriptional gene silencing
A gene-silencing effect that controls gene expression after transcription, often mediated by small non-coding RNAs such as small interfering RNAs (siRNAs) and microRNAs (mi RNAs).
and somatic mutations in core components of the miRNA biogenesis machinery promote oncogenesis, and provide specific examples of how certain RNA-binding proteins and cell signalling pathways contribute to cancer through their control of miRNA expression. With these examples, we aim to highlight emerging themes and the relevance of the miRNA biogenesis pathway in cancer. 29 . Binding of the ~22-nucleo tide miRNA to target mRNA mediates mRNA degradation and blocks translation 30 . The majority of miRNA genes are transcribed by RNA polymerase II (Pol II) in the nucleus, and the primary mi RNAs (pri-mi RNAs) are capped, spliced and polyadenylated 31 . Approximately 30% of mi RNAs are processed from introns of proteincoding genes, whereas most other mi RNAs are expressed from dedicated miRNA gene loci. An individual primiRNA can either produce a single miRNA or contain clusters of two or more mi RNAs that are processed from a common primary transcript. Nonetheless, these long pri-mi RNAs are cleaved by Microprocessor, which comprises the double-stranded RNase III enzyme DROSHA and its essential cofactor, the double-stranded RNA (dsRNA)-binding protein DiGeorge syndrome critical region 8 (DGCR8) 32, 33 . DROSHA contains two RNase III domains, each of which cleaves one strand of the dsRNA towards the base of stem-loop secondary structures contained within pri-mi RNAs to liberate ~60-70-nucleotide hairpin-shaped precursor mi RNAs (pre-mi RNAs) [32] [33] [34] [35] . Microprocessor recognizes the single-stranded RNA (ssRNA)-stem junction as well as the distance from the terminal loop region. It specifically cleaves the dsRNA ~11 bp from the junction with the flanking ssRNA to produce hairpin-shaped pre-mi RNAs with an overhang at the 3ʹ end of either 2 nucleotides (group I mi RNAs) or 1 nucleotide (group II mi RNAs) [36] [37] [38] [39] . Although the core components, DROSHA and DGCR8, are required for the biogenesis of almost all mi RNAs in the cell, and Microprocessor activity can be reconstituted in vitro with recombinant DROSHA and DGCR8 proteins 32, 35 , numerous accessory factors are known to have a role in pri-miRNA processing in cells (discussed in more detail below). The pre-mi RNAs are then exported from the nucleus to the cytoplasm by exportin 5 (XPO5) [40] [41] [42] and further processed by DICER1, an RNase III enzyme that measures from the 5ʹ and 3ʹ ends of the pre-miRNA 43 . DICER1 binding to the end of the pre-miRNA positions its two catalytic RNase III domains so that asymmetrical cleavage of the dsRNA stem, close to the terminal loop sequence, produces the mature ~22-nucleotide miRNA duplex with 2-nucleotide 3ʹ overhangs 44 . DICER1 associates with transactivation-responsive RNA-binding protein (TRBP; also known as TARBP2), which binds to dsRNA 45 . Although it is not required for pre-miRNA processing by DICER1, TRBP enhances the fidelity of DICER1-mediated cleavage of a subset of pre-mi RNAs in a structure-dependent manner and alters miRNA guide-strand selection by triggering the formation of isomi RNAs, which are 1 nucleotide longer than the regular mi RNAs 46, 47 . TRBP also physically bridges DICER1 with the Argonaute proteins (AGO1, AGO2, AGO3 or AGO4) to participate in the assembly of the miRNAinduced silencing complex (miRISC) 45 . One strand of the mature miRNA (the guide strand) is bound by an Argonaute protein and retained in the miRISC to guide the complex, together with members of the GW182 family of proteins, to complementary target mRNAs for post-transcriptional gene silencing. This occurs in processing bodies (P-bodies), which are the cytoplasmic foci that are induced by mRNA silencing and decay but are not necessarily required for miRNA-mediated gene silencing [48] [49] [50] (FIG. 1) .
Pri-miRNA transcription in cancer miRNA biogenesis initiates with the transcription of the pri-miRNA, and this step is dysregulated in multiple human cancers. A considerable number of human miRNA genes are located at fragile sites or in genomic regions that are deleted, amplified or translocated in cancer 51 . These genomic variations alter pri-miRNA transcription and miRNA expression, which leads to the aberrant expression of downstream target mRNAs that can promote cancer initiation and progression 51, 52 . For example, the locus including miR-15 and miR-16 on chromosome 13q14 is frequently deleted in B-CLL, resulting in the loss or reduced expression of these two mi RNAs in ~70% of B-CLLs
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. miR-15 and miR-16 normally control apoptosis by targeting BCL-2 mRNAs 53 . In another example, a point mutation in the miR-128b (also known as miR-128-2) gene blocks the processing of pri-miR-128b and reduces the levels of mature miR-128b, thus leading to glucocorticoid resistance in acute lymphoblastic leukaemia (ALL) cells with the mixed-lineage leukaemia (MLL)-AF4 (also known as KMT2A-AFF1) translocation 54 . In addition to genomic alterations, dysregulated miRNA expression can arise from alterations in tumour suppressor or oncogenic factors that function as transcriptional activators or repressors to control pri-miRNA transcription. For example, expression of the miR-34 family of mi RNAs is driven by p53 and reflects the status of p53 in human cancers [55] [56] [57] [58] [59] . The miR-34a, miR-34b and miR-34c mi RNAs repress growth-promoting genes and coordinate with other members of the p53 tumoursuppressive network to inhibit uncontrolled cell proliferation and to promote apoptosis [55] [56] [57] [58] [59] . In addition, the proto-oncoprotein MYC activates expression of oncogenic mi RNAs, including the miR-17~92 cluster, in cancer 60, 61 . These MYC-target mi RNAs promote cancer progression by controlling the expression of E2F1, thrombospondin 1 (THBS1), connective tissue growth factor (CTGF) and other target mRNAs to regulate cell cycle progression and angiogenesis 60, 61 . MYC can also contribute to the widespread repression of tumoursuppressive mi RNAs in B cell lymphoma 62 . Expression of Nature Reviews | Cancer is frequently suppressed in human tumours. These mi RNAs are known to directly target the mRNAs encoding the zinc-finger E-box-binding homeobox (ZEB) transcription factors, ZEB1 and ZEB2, which suppress the expression of epithelial genes to promote the epithelial-mesenchymal transition (EMT) 63 . Interestingly, ZEB1 and ZEB2 directly bind to a regulatory element at the miR-200 promoter to repress transcription of miR-200 as part of a negative regulatory feedback loop that promotes EMT 64 . Many other cancer-associated transcription factors also aberrantly regulate miRNA transcription in cancer. Therefore, transcriptional dysregulation -through either genetic loss of miRNA genes or aberrant transcription factor activity -is an important mechanism for altered miRNA expression in cancer.
CpG islands
Epigenetic modification of histone proteins and DNA controls local chromatin structure and has an important role in the regulation of both coding and non-coding gene expression. Indeed, epigenetic alteration is a common feature of cancer pathogenesis that drives the dysregulation of miRNA expression. The CpG islands at the gene promoters of tumour-suppressive mi RNAs are frequently hypermethylated in cancer, thereby leading to the epigenetic silencing of these mi RNAs. Treatment of cancer cells with DNA-demethylating agents can reactivate the expression of tumour-suppressive mi RNAs, such as miR-148a, miR-34b, miR-34c and miR-9, that inhibit tumour growth and metastasis 65 . In addition to DNA methylation, histone modifications have important roles in chromatin remodelling and cooperate with DNA methylation to suppress miRNA expression in cancer 66 . Overall, epigenetic silencing is an important mechanism underlying miRNA repression in cancer.
Defective Microprocessor in cancer
The nascent pri-miRNA generated by Pol II forms a typical secondary structure consisting of a stem-loop hairpin flanked by ssRNA that is a substrate for cleavage by Microprocessor to generate pre-miRNA intermediates. A negative feedback mechanism involving the Microprocessor-mediated cleavage and destabilization of DGCR8 mRNA operates to help to control the relative DGCR8 expression level and to maintain the homeostatic control of miRNA biogenesis in cells [67] [68] [69] . The expression and function of the Microprocessor components are often dysregulated in cancer. For example, copy-number gain or overexpression of DROSHA occurs in more than 50% of advanced cervical squamous cell carcinomas 70 . In addition, DROSHA expression levels are upregulated in multiple types of cancer (TABLE 1) . The increased expression of DROSHA alters the global miRNA expression profile and promotes cell proliferation, migration and invasion, which contributes to cancer progression 70, 71 . Conversely, DROSHA expression levels have been shown to be downregulated in many other types of cancer. DROSHA downregulation results in decreased miRNA expression 13 and is correlated with metastasis, invasion 72 and poor patient survival 13, 14, 73, 74 ( 15 , suggesting that DROSHA can function as a tumour suppressor to inhibit cancer progression in some contexts. Why DROSHA is upregulated in certain types of cancer but downregulated in others is not well understood, but one possibility is that different cancers have different genetic or epigenetic mechanisms controlling DROSHA expression, thus resulting in the abnormal expression of oncogenic or tumour-suppressive mi RNAs in a given cancer type.
Mutational analysis revealed that DROSHA is frequently mutated in Wilms tumour samples [21] [22] [23] [24] (table) ). More than 70% of the DROSHA mutations occur at E1147, a metalbinding residue in the RNase IIIb domain. The recurrent somatic missense mutation E1147K interferes with metal binding and therefore affects the function of DROSHA in the processing of pri-mi RNAs through a dominantnegative mechanism [21] [22] [23] [24] . As a result, mature mi RNAs are globally downregulated in DROSHA-mutated Wilms tumours [21] [22] [23] [24] . Several missense mutations and a splicesite mutation of the DROSHA gene have been found in ovarian cancer; however, these mutations do not affect DROSHA expression levels. Therefore, it remains to be characterized whether the functions of DROSHA are affected by these mutations 14 . In addition, DROSHA was found to be alternatively spliced in melanoma and teratocarcinoma cells 75 . The splice variants encode carboxy-terminal-truncated DROSHA proteins that The long pri-mi RNAs are cleaved by Microprocessor, which includes DROSHA and DiGeorge syndrome critical region 8 (DGCR8), to produce the 60-70-nucleotide precursor mi RNAs (pre-mi RNAs). The pre-mi RNAs are then exported from the nucleus to the cytoplasm by exportin 5 (XPO5) and further processed by DICER1, a ribonuclease III (RIII) enzyme that produces the mature mi RNAs. One strand of the mature miRNA (the guide strand) is loaded into the miRNA-induced silencing complex (miRISC), which contains DICER1 and Argonaute (AGO) proteins, directs the miRISC to target mRNAs by sequence complementary binding and mediates gene suppression by targeted mRNA degradation and translational repression in processing bodies (P-bodies). TRBP, transactivation-responsive RNA-binding protein. Pre-miRNA export in cancer Pre-mi RNAs are exported into the cytoplasm to be processed into mature mi RNAs. The export of pre-mi RNAs is mediated by XPO5 and its cofactor, RanGTP 41 . Three recurrent heterozygous XPO5-inactivating mutations were identified in sporadic colon, gastric and endometrial tumours with microsatellite instability 76 (FIG. 2 ; see Supplementary information S1 (table)). These XPO5 mutations impair pre-miRNA export and result in an accumulation of pre-mi RNAs in the nucleus, leading to defects in miRNA biogenesis. In addition, genetic and epigenetic association studies revealed that XPO5 genetic variation and expression level are associated with the risk of breast cancer 77 . Therefore, XPO5 dysregulation contributes to miRNA processing defects and tumorigenesis.
Pre-miRNA processing in cancer DICER1 mutations. After being exported to the cytoplasm, pre-mi RNAs are then processed by DICER1 to form ~22-nucleotide mature mi RNAs 78 . DICER1 is a large multi-domain nuclease that contains two helicase domains, a dimerization domain, a Piwi-ArgonauteZwille (PAZ) domain, two RNase III domains (RNase IIIa and RNase IIIb) and a dsRBD (FIG. 2; see Supplementary information S1 (table) ). In addition to its function in pre-miRNA cleavage, DICER1 is required for the assembly of the minimal miRISC that executes miRNA function in repressing target gene expression 48 . Depletion of DICER1 in cancer cells or mouse models promotes cell growth and tumorigenesis, indicating the important function of DICER1 in oncogenesis 15, 79 . Furthermore, Dicer is considered a haploinsufficient tumour suppressor gene, as loss of a single Dicer1 allele reduces survival in a mouse model of lung cancer 79 . Heterozygous germline DICER1 mutations were first identified to be responsible for pleuropulmonary blastoma (PPB), a rare paediatric lung tumour that arises during fetal lung development and is often part of an inherited cancer syndrome (Online Mendelian Inheritance in Man (OMIM) #601200) 16 . Germline frameshift or nonsense mutations mainly affect DICER1 upstream of the region encoding RNase III domains (FIG. 2) , resulting in truncated DICER1 proteins lacking the C-terminal catalytic domains. DICER1 loss of hetero zygosity (LOH) is almost never observed in human tumours, and homozygous Dicer1 loss is generally selected against in mouse cancer models 79 . Although more than 50% of heterozygous germline DICER1 mutation carriers are clinically unaffected, the tumours that develop in PPB patients are typically associated with another important group of DICER1 mutations: recurrent somatic mutations in the RNase IIIb domain 18, 80 . The mutation hot spots of the RNase IIIb domain occur in the metal-binding residues (E1705, D1709, G1809, D1810 and E1813) 18 (FIG. 2) ; this domain is responsible for the cleavage of the 3ʹ end of the mi RNAs derived from the 5ʹ side of the pre-miRNA hairpin called 5p mi RNAs. These mutations do not change DICER1 protein expression but instead cause defects in the function of the RNase IIIb domain. As a result, the maturation of 5p mi RNAs is specifically blocked, while the processing of 3p mi RNAs (mi RNAs derived from the 3ʹ side of the pre-miRNA hairpin) remains unaffected, leading to the global loss of 5p mi RNAs in cancer 17, 18 . Particularly, DICER1 RNase IIIb mutations strongly reduce the expression of the members of the let-7 tumour-suppressive miRNA family (that are all 5ʹ derived), which probably helps to explain the selective pressures that give rise to this specific mutation spectrum in cancers. Interestingly, modelling of PPB in mice supports the idea that Dicer1 deletion in the distal airway epithelium causes non-cellautonomous tumour initiation, whereby Dicer1 loss in the epithelium causes the underlying mesenchymal cells to be malignantly transformed 81 . DICER1 mutations are frequently found in different types of inherited tumours: 90 and others 91 (see Supplementary information S1 (table)). As a result, patients harbouring these DICER1 mutations have reduced DICER1 expression and/or impaired DICER1 function, which cause the abnormal expression of mi RNAs and contribute to the pathogenesis of cancer. As such, DICER1 mutation is considered a tumour predisposition syndrome known as DICER1 syndrome 20 . This topic has recently been reviewed in detail 19 . In addition to genetic mutations of DICER1, DICER1 expression is often dysregulated in cancer. Similar to that of DROSHA, DICER1 expression can be increased or decreased in cancer, depending on the cancer type (TABLE 1) . Many oncoproteins and dysregulated tumour suppressors regulate cancer progression by targeting DICER1 expression. For example, the p53 family member TAp63 directly binds to the promoters of DICER1 and miR-130b and drives their expression to suppress tumorigenesis and metastasis 92 . Overall, both genetic mutation and dysregulation of DICER1 can result in aberrant miRNA expression and tumorigenesis.
TRBP mutations. Impaired function of TRBP also contributes to miRNA dysregulation in cancer. Sequencing of the genes encoding the miRNA processing machinery revealed two frameshift mutations of TRBP in sporadic and hereditary carcinomas with microsatellite instability 93, 94 (FIG. 2; see Supplementary information S1 (table) ). These mutations cause reduced TRBP and DICER1 expression as well as defective processing of pre-mi RNAs. Re-introduction of wild-type TRBP in the mutated cell lines rescued TRBP and DICER1 expression, restored miRNA processing and suppressed cancer cell growth in vitro and in vivo 93 . Interestingly, the expression of TRBP is repressed in the cancer stem cell (CSC) population of Ewing sarcoma family tumour (ESFT), which results in the miRNA profile of ESFT CSCs that is required for CSCassociated self-renewal and tumour growth 95 . Therefore, TRBP-mediated miRNA processing has an important tumour-suppressive role in normal cells.
Other miRNA regulators in cancer Aberrant expression of or mutations in the genes encoding key components of the miRNA biogenesis pathway contributes to the global repression of mi RNAs in cancer. However, a widespread suppression of miRNA expression has been observed in cancers with normal expression of the miRNA biogenesis machinery. This suggests that other pathways regulating miRNA processing are dysregulated in cancer. We highlight below recent discoveries of selected cancer-relevant pathways involved in the regulation of miRNA biogenesis.
Regulators of Microprocessor.
The original characterization of a large DROSHA-containing complex identified multiple classes of RNA-binding proteins, including the DEAD (Asp-Glu-Ala-Asp) box helicases DDX5 (also known as p68) and DDX17 (also known as p72), Ewing sarcoma family proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) 32 . These Microprocessorassociated proteins can directly affect Microprocessor activity, and alterations in this regulation can result in aberrant miRNA biogenesis in cancer 96 . Other factors might also regulate Microprocessor activity in cancer: for example, the tumour suppressor BRCA1 interacts with multiple Microprocessor regulators to facilitate miRNA biogenesis 97 . Moreover, RNA-binding proteins such as KH type-splicing regulatory protein (KSRP; also known as FUBP2) 98 , serine/arginine-rich splicing factor 1 (SRSF1) 99 , hnRNP A1 (REFS 100, 101) and FUS (also known as TLS) 102 bind to certain regions of primi RNAs (stem or terminal loop) and facilitate DROSHA recruitment and function (FIG. 3) .
In addition to regulating Microprocessor activity, DDX5 and DDX17 function as bridging factors for important oncoproteins or tumour suppressors to regulate miRNA biogenesis in cancer. For example, the tumour suppressor protein p53 regulates miRNA biogenesis through association with DDX5 and DDX17. In response to DNA damage, the level of p53 expression increases, which enhances the expression levels of tumour-suppressive mi RNAs including miR-34a, miR-16-1, miR-143 and miR-145 (REF. 103 ). In contrast to miR-34a, which is a transcriptional target of p53 (REF. 55 ), the other mi RNAs are post-transcriptionally regulated by p53. Mediated by DDX5 and DDX17, p53 interacts with the DROSHA complex and promotes the processing of tumour-suppressive pri-mi RNAs. Accordingly, miRNA processing is hindered in p53-mutant cells 103 . Given that p53 is frequently mutated in human cancer, dysregulation of miRNA biogenesis by p53 mutation might account for the widespread miRNA repression in cancer (FIG. 3) .
Cell signalling control. Cell signalling pathways also modulate Microprocessor activity to dynamically control pri-miRNA processing and miRNA expression in cancer 96 (FIG. 3) . For example, SMADs -which transduce transforming growth factor-β (TGFβ) and bone morphogenetic protein (BMP) signalling -associate with DDX5 and promote miRNA processing by binding to a consensus sequence in the stem region of primi RNAs 104, 105 . Moreover, the core biogenesis machinery components, including DROSHA, DGCR8, DICER1 and TRBP, are subject to post-translational control such as phosphorylation and/or acetylation (reviewed in REFS 106, 107) . The effect of these protein modifications, and their possible dysregulation in cancer, remains to be determined.
It was recently found that the Hippo pathway controls Microprocessor activity 108 . The Hippo pathway controls organ size by regulating cell proliferation and differentiation in response to cell density 109 . Given its key role in regulating organ size and cell proliferation, it is perhaps not surprising that the Hippo signalling pathway is frequently perturbed in a variety of human cancers 109 . miRNA biogenesis is activated by cell-cell contact and Hippo signalling 108, 110 . Mechanistically, it was found that the Hippo downstream effector Yes-associated protein 1 (YAP1) post-transcriptionally regulates miRNA UUUUUU Nature Reviews | Cancer and BRCA1 modulate Microprocessor activity in cancer; cell signalling pathways such as Hippo and bone morphogenetic protein (BMP) regulate pri-miRNA processing; and LIN28 proteins selectively block the processing of pri-let-7. c | Genetic mutations in and transcriptional regulation of exportin 5 (XPO5) affect XPO5-mediated precursor miRNA (pre-miRNA) export in cancer. d | Pre-miRNA processing in cancer is regulated in the following ways: hypoxia, genetic mutations and transcriptional regulation modulate DICER1 expression and function to control pre-miRNA cleavage in cancer; LIN28 proteins selectively bind to pre-let-7 and recruit terminal uridylyltransferase 4 (TUT4), TUT7 and DIS3-like exonuclease 2 (DIS3L2) to degrade pre-let-7; and hypoxia-induced and epidermal growth factor receptor (EGFR)-induced phosphorylation of Y393 of Argonaute 2 (AGO2) inhibits pre-miRNA processing. e | miRNA function is regulated in the following ways: competing endogenous RNA (ceRNA) inhibits miRNA function in cancer (high-mobility group AT-hook 2 (HMGA2) blocks let-7 function), as do mutations of miRNA-binding sites in non-small cell lung cancer (mutation of let-7-binding site in the 3ʹ untranslated region (UTR) of KRAS mRNA). hnRNP, heterogeneous nuclear ribonucleoprotein; KDM6, lysine-specific demethylase 6; KSRP, KH-type splicing regulatory protein; Pol II, RNA polymerase II; RIII, ribonuclease III; SRSF1, serine/arginine-rich splicing factor 1; TGFβ, transforming growth factor-β; TRBP, transactivation-responsive RNA-binding protein; YAP, Yes-associated protein; ZEB, zinc-finger E-box-binding homeobox. biogenesis by targeting DDX17. In in vitro cell culture systems, at low cell density, the growth-suppressive Hippo pathway is inactive, and nuclear YAP1 binds to and sequesters DDX17 to suppress pri-miRNA processing, whereas at high cell densities, the Hippo pathway is active, which leads to YAP1 phosphorylation and its retention in the cytoplasm. When YAP1 is cytoplasmic, DDX17 is able to bind to a specific sequence motif in pri-miRNA, associate with Microprocessor and enhance miRNA biogenesis. Accordingly, inactivation of the Hippo pathway or constitutive activation of YAP1, which occurs in cancer cells, results in widespread miRNA suppression both in human cancer cell lines and in mouse tumour models 108 . It will be interesting to explore whether Hippo signalling is responsible for the widespread repression of miRNA expression in cancer.
Genetic alterations Mutations and deletions

Epigenetic regulation
Stress response. Rapidly growing tumours often experience hypoxia owing to the limited oxygen supply in the tumour microenvironment. Interestingly, miRNA expression and function are dynamically regulated under stress conditions 111 . Oncogenic epidermal growth factor receptor (EGFR) signalling is activated by hypoxia to promote cell growth and oncogenesis 112 . Identification of the EGFR protein complex in serum-starved EGFtreated HeLa cells revealed that EGFR interacts with AGO2 (REF. 113 ). In response to hypoxia, EGFR induces the phosphorylation of AGO2 at Y393, which inhibits the interaction between DICER1 and AGO2 and blocks miRNA accumulation. Furthermore, EGFR-mediated AGO2-Y393 phosphorylation is required for cell survival and invasion under hypoxic conditions and is associated with poor survival rates in patients with breast cancer 113 . In addition, recent studies uncovered the important role of hypoxia in suppressing DROSHA and DICER1 expression in cancer cells, which results in aberrant miRNA biogenesis and promotes tumour progression 114, 115 . These studies provide an interesting link between hypoxia and miRNA repression in cancer and uncover a novel oncogenic role of hypoxia in regulating miRNA biogenesis during tumorigenesis [113] [114] [115] (FIG. 3) .
LIN28-mediated blockade of let-7. The let-7 miRNA family members function as tumour suppressors in multiple cancer types by inhibiting expression of oncogenes and key regulators of mitogenic pathways [116] [117] [118] . In humans, there are 12 let-7 family members (let-7a-1, let-7a-2, let-7a-3; let-7b; let-7c; let-7d; let-7e; let-7f-1, let-7f-2; let-7g; let-7i; miR-98) located at 8 unlinked chromosomal loci. The let-7 mi RNAs are downregulated in numerous cancer types, and low let-7 expression levels correlate with poor prognosis [119] [120] [121] [122] . The expression of the let-7 miRNA family is coordinately regulated by the paralogous RNA-binding proteins LIN28A and LIN28B during early embryonic development [123] [124] [125] [126] . Reactivation of this embryonic pathway in adult cells by expression of LIN28A and LIN28B is sufficient to promote cellular transformation and tumorigenesis in vitro and in vivo [127] [128] [129] [130] . Of note, expression of LIN28B is sufficient to drive neuroblastoma, T cell lymphoma, intestinal adenocarcinoma, Wilms tumour (nephroblastoma) and hepatocellular carcinoma in mouse models 128, [130] [131] [132] [133] . LIN28 proteins block cell differentiation, promote cell proliferation and alter cellular metabolism to promote tumorigenesis 134, 135 . The repression of the let-7 family in these contexts is crucial, as tumour formation is suppressed by enforced expression of let-7g, and genetic deletion of a let-7 locus (let7c2 and let7b) recapitulated the effects of LIN28B overexpression in the intestine [127] [128] [129] 133 . Depletion of LIN28A or LIN28B in human cancer cell lines results in decreased cell proliferation, cell invasion and tumorigenicity 129, 136 , and withdrawal of LIN28B expression can revert liver tumorigenesis in mice 130 . At least 15% of all human cancer samples investigated are characterized by reactivation of either LIN28A or LIN28B, with a corresponding reduction in let-7 levels 129 . Moreover, elevated LIN28A or LIN28B expression correlates with poor prognosis and decreased patient survival 129, 131, [137] [138] [139] [140] . Considering also that LIN28A and LIN28B expression may characterize distinct tumorigenic subpopulations of cells within the tumour, known as tumour-initiating cells or CSCs 141 , these studies underscore the importance of the LIN28 proteins in promoting and characterizing various human malignancies and suggest that this pathway represents an important new target for effective cancer therapies.
Mechanistically, LIN28 proteins selectively bind to the terminal loop region of pre-let-7 through RNA-protein interactions through its cold-shock domain and tandem Cys-Cys-His-Cys (CCHC)-type zinc-fingers 142, 143 . LIN28 proteins recruit two alternative 3ʹ terminal uridylyltransferases (TUTases), ZCCHC11 (also known as TUT4) and ZCCHC6 (also known as TUT7), to pre-let-7 RNA [144] [145] [146] . These TUTases are key mediators in the LIN28 blockade of let-7 biogenesis, in which they catalyse the addition of an oligouridine tail to pre-let-7. Uridylated pre-let-7 is resistant to DICER1 processing and is rapidly degraded to prevent let-7 biogenesis in LIN28A-or LIN28B-expressing cells 125 . The enzyme responsible for this decay pathway was recently identified as DIS3L2, a novel 3ʹ-5ʹ exonuclease that selectively degrades 3ʹ oligouridylated (>12 uridines) RNA [147] [148] [149] (FIG. 3) . Intriguingly, DIS3L2 is a tumour suppressor gene that is deleted in Perlman syndrome, which is characterized by fetal overgrowth and cancer predisposition, as well as in ~30% of sporadic Wilms tumours analysed 150 . Considering the strong links between DROSHA and DICER1 mutations in Wilms tumours, the demonstrated ability of LIN28A and LIN28B to promote tumorigenesis as well as the tumour-suppressive role of DIS3L2, it is perhaps likely that loss of let-7 expression and/or function is a unifying driver of Wilms tumours and of other types of cancer. This let-7 loss might be accomplished by any of the aforementioned mechanisms as well as by the possible titration of let-7 function via the considerable overexpression of mRNAs containing let-7 binding sites, as was recently suggested for HMGA2 (REF. 151 ). Another possible mechanism involves mutations in the let-7 binding sites of key downstream targets, thus relieving these mRNAs from let-7 regulation. In support of this, a single-nucleotide polymorphism (SNP) in a let-7 binding site in the 3ʹ UTR of the KRAS mRNA has been genetically associated with an increased risk of cancer 152 (FIG. 3) .
Oncofetal genes
Genes that are typically highly expressed during fetal development and repressed in adult life, and reactivated in cancers.
Conclusions and perspectives
Discoveries over the past 15 years have provided substantial insights into the mechanisms controlling miRNA biogenesis. The identification and characterization of the core miRNA biogenesis machinery provided the framework for recent developments that uncovered cancer-causing mutations in miRNA biogenesis components as well as for the identification of cellular signalling and regulatory pathways that control different subsets of mi RNAs. Although clear examples of individual mi RNAs with oncogenic function have been described, the net effect of widespread miRNA depletion is to promote tumorigenesis. This was first demonstrated in human cancer cells and mouse models and is strongly supported by the mutations recently identified in core miRNA biogenesis genes.
Analogous to the defective differentiation phenotype of miRNA-deficient embryonic stem cells, it seems that also in the context of cancer the dominant function of mi RNAs is to help to maintain differentiated cells in a particular cell state or lineage 153, 154 . In this model, loss of mi RNAs facilitates epigenetic reprogramming, loss of differentiated cell identity and adoption of an undifferentiated cancer phenotype. Indeed, DGCR8 depletion is sufficient to reprogramme human primary keratinocytes to induced pluripotent-like cells 155 . Furthermore, miRNA expression is globally elevated in confluent cells, which is consistent with their roles in suppressing cell proliferation and in coordinating the altered metabolic demands of less-proliferative cells and tissues 108, 110 . Presumably this is how widespread miRNA depletion -through loss of components of the biogenesis machinery or loss of growth-suppressive signalling pathways (for example, the Hippo pathway) -contributes to rapid cancer cell proliferation and tumour growth. In this way, widespread loss of mi RNAs functionally cooperates with other cancer hallmarks to regulate cancer progression 156 . Is loss of any particular miRNA or miRNA family responsible for these tumorigenic effects? One good candidate is the let-7 family. The let-7 family is required in adult fibroblasts to suppress the expression of a mid-gestation embryonic gene signature that is enriched with oncofetal genes 157 . Conversely, antagonizing let-7 with antisense oligonucleotides can enhance reprogramming to induced pluripotent stem cells, suggesting that let-7 has a dominant role in stem cell differentiation 158 . Indeed, re-introduction of let-7 into miRNA-deficient mouse embryonic stem cells rescued the stem cell differentiation phenotype 158 ; similarly, restoration of let-7 expression was shown to effectively inhibit growth of lung and breast cancer cells, as well as in mouse models of hepatocellular carcinoma and Wilms tumours 118, 159, 160 . Thus, let-7 emerges as a key regulator in stem cell biology and tumorigenesis and, as outlined in this Review, there are multiple mechanisms by which cancer cells inactivate this miRNA 'guardian' of differentiation, proliferation and metabolic reprogramming.
Future work promises to illuminate the most relevant mi RNAs in the context of different cancer types and will probably uncover additional pathways that control the expression of individual mi RNAs or of miRNA subsets. Studies in this area will be facilitated by the recent advances in genome engineering using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat-CRISPR-associated protein 9) technology, in mouse modelling and in the use of organoid culture systems to model cancer 161 , as well as by the application of high-throughput sequencing technologies that will uncover cancer-causing mutations in patients and that can be applied in the laboratory to examine the effects of possible regulators on global miRNA expression profiles 21 . With this powerful toolkit in hand, the next several years promise exciting discoveries that will help to unlock the secrets of miRNA dysregulation in cancer. Understanding the molecular and cellular pathways controlling miRNA biogenesis and how these mechanisms go awry in cancer will identify promising therapeutic targets that might be readily manipulated by small pharmacological agents to allow restoration of miRNA expression profiles and to bypass the challenges associated with delivering synthetic miRNA mimics or antagomiRs.
